Diabetes and mass spectrometry

Diabetes/Metabolism Research and Reviews

Volumn 17, Issue 2, 2001, Pages 99-112

  Lapolla, A ^a   Fedele, D ^a   Traldi, P ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

Author keywords

Diabetes; Haemoglobin; Immunoglobulins; Mass spectrometry; Non enzymatic protein glycation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA GLOBIN; ANTIBODY; ANTIGEN; BETA GLOBIN; BIOCHEMICAL MARKER; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HEXOSE; IMMUNOGLOBULIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; PLASMA PROTEIN; PROTEIN;

ACCURACY; ADULT; AGED; ANALYTIC METHOD; CHEMICAL INTERACTION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOPATHOLOGY; IN VITRO STUDY; MASS SPECTROMETRY; MEDICAL INFORMATION; METABOLIC REGULATION; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; MONITORING; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; REVIEW; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

GLOBINS; HEMOGLOBIN A, GLYCOSYLATED; HEMOGLOBINS; HUMANS; IMMUNOGLOBULIN G; MASS SPECTROMETRY; MOLECULAR CONFORMATION; PROTEIN CONFORMATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 0035013583     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.189     Document Type: Review

References (87)

1. Blood glucose control and microvascular and macrovascular complications in diabetes
2. The effect of intensive treatment of diabetes on the development and progression of the long term complications in insulin-dependent diabetes mellitus
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
4. Diabetes complications: Why is glucose potentially toxic?
5. Haemoglobin components in patients with diabetes mellitus
6. Chemistry of nonenzymatic browning II
7. Glycation of aminoacid groups in proteins
8. Advanced glycosylation end-products and the biochemical basis of diabetic complications
9. Non-enzymatic glycosylation and browning of protein in vivo
10. The clinical significance of glycation
11. Glucose autoxidation and protein modification: The potential role of "autoxidative glycosylation" in diabetes mellitus
12. Protein glycation and oxidative stress in diabetes mellitus and ageing
13. The Maillard reaction in vivo
14. Role of oxidative stress in development of complications in diabetes
15. Role of oxidative stress in diabetic complications: A new perspective on an old paradigm
16. Non-enzymatic glycosylation and the pathogenesis of diabetic complications
17. Glycation, oxidation and lipoxidation in the development of the complications of diabetes: A carbonyl stress hypothesis
18. Non-enzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity
19. High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: A potential mechanism for the removal of senescent macro-molecules
20. Cloning expression of RAGE: A cell surface receptor for advanced glycosylation end-products of proteins
21. Cellular receptors for advanced glycation end-products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
22. Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin
23. Observations on the chromatographic heterogeneity of normal adult and fetal hemoglobin: A study of the effect of crystallization and chromatography on the heterogeneity and isoleucine content
24. The role of glycohemoglobin and other proteins in diabetes management
25. Specific quantitation by HPLC of protein (lysine)-bound glucose in human serum albumin and other glycosylated proteins
26. Fructosamine: A new approach to the estimation of serum glycosyl protein: An index of diabetic control
27. Immunocytochemical detection of advanced glycation end-products in diabetic tissues using monoclonal antibody to pyrraline
28. Immunochemical detection of advanced glycosylation end-products
29. Structure elucidation of a senescence crosslink from human extracellular matrix
30. Pentosidine: A molecular marker for the cumulative damage to proteins in diabetes, aging and uremia
31. Pentosidine formation in skin correlates with severity of complications in individuals with long standing IDDM
32. Identification of carboxy-methyllysine as a degradation product of fructoselysine in glycated proteins
33. Advanced Maillard reaction products as markers for tissue damage in diabetes and uremia: Relevance to diabetic nephropathy
34. The serum concentration of advanced glycation end-product Nε (carboxy methyl) lysine is increased in uremia
35. Accumulation of carbonyls accelerated the formation of pentosidine and advanced glycation end-products: Carbonyl stress in uremia
36. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy
37. Clearance of pentosidine, an advanced glycation end-product, by different modalities of renal replacement therapy
38. Alterations in non-enzymatic biochemistry in uremia; origin and significance of "carbonyl stress" in long-term uremic complications
39. Aging of proteins: Immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo
40. Immunocytochemical detection of advanced glycosylation end-products in diabetic tissues using monoclonal antibody to pyrraline
41. Crosslines. Fluorophores in the AGE-related cross-linked proteins
42. Crosslines A and B as candidates for the fluorophores in age and diabetes related cross-linked proteins and their diacetates produced by Maillard reaction of Nε-acetyl-lysine with glucose
43. New biomarkers of Maillard reaction damage to proteins
44. Matrix assisted laser desorption ionization mass spectrometric studies on protein glycation. The reaction of ribonuclease with hexoses
45. Advanced glycosylation: Chemistry, biology and implications for diabetes and aging
46. Matrix-assisted laser desorption/ionization capabilities in the study of non enzymatic protein glycation
47. Fast-atom bombardment mass spectrometry
48. Chromatographic quantification of plasma and erythrocyte pentosidine in diabetic and uremic subjects
49. Detection of 3-deoxyfructose and 3-deoxyglucosone in human urine and plasma: Evidence for intermediate stages of the Maillard reaction in vivo
50. Aging of proteins: Isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose
51. Detection of an advanced glycosylation product bound to protein in situ
52. Collisional spectroscopy as a screening procedure for the determination of 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole from acid hydrolysis of β-poly (L-Lysine) and β-albumin
53. Absence of brown products FFI in non-diabetic and diabetic rat collagen
54. Evidence of acid hydrolysis as responsible for 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole (FFI) production
55. Parent ion scan in the identification of 2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole related compounds in collagen samples of diabetic rats
56. Identification of furoyl-containing advanced glycation products in collagen samples from diabetic and healthy rats
57. The lysine glycation 1. A preliminary investigation on the products arising from the reaction of protectant lysine and D-glucose
58. Mechanism of formation of putative advanced glycosylation end-products and protein cross-link 2-(2-furoyl)-4(5)-2-furanyl)-1-H-imidazole
59. Matrix assisted laser desorption/ionization mass spectrometry
60. A study on in vivo glycation processes by matrix assisted laser desorption ionization mass spectrometry
61. The in vivo glycation of lysozyme and the influence of buffer concentration investigated by mass spectrometry
62. A new effective method for the evaluation of glycated intact plasma proteins in diabetic subjects
63. Sites of non enzymatic glycosylation of human hemoglobin
64. Glycated hemoglobin: Methodologies and clinical applications
65. The in vivo glycooxidation of α and β globins investigated by matrix assisted laser desorption ionization mass spectrometry
66. A highly specific method for the characterization of glycation and glycooxidation products of globins
67. Direct evaluation of glycated and glycooxidized globins by matrix assisted laser desorption ionization mass spectrometry
68. Evaluation of glycated globins by matrix-assisted laser desorption/ionization mass spectrometry
69. Further considerations on the use of matrix-assisted laser desorption/ionization mass spectrometry in the analysis of glycated globins
70. Potential of electrospray mass spectrometry for quantifying glycohaemoglobin
71. Evidence for an increased glycation of IgG in diabetic patients
72. Effect of non-enzymatic glycation on the structure of immunoglobulin G
73. Impairment by glycation on the structure of immunoglobulin G, a Fc fragment function
74. Polyclonal immunoglobulin M: Location of glycation sites
75. Evaluation of IgG glycation levels by matrix assisted laser desorption/ionization mass spectrometry
76. Impaired immuno-globulin G Fc fragment function in diabetes is caused by a mechanism different from glycation
77. Impaired agglutination of IgM resulting from non-enzymatic glycation in diabetes mellitus
78. Glycation of monoclonal antibodies impairs their ability to bind antigen
79. Nonenzymatic glycation of immunoglobulins does not impair antigen-antibody binding
80. Nonenzymatic glycation of human immunoglobulins does not impair their immunoreactivity
81. Matrix-assisted laser desorption/ionization mass spectrometry, enzymatic digestion, and molecular modeling in the study of non-enzymatic glycation of IgG
82. Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy Kidney
83. Renal fate of circulating advanced glycated end-products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells
84. Modification of low density lipoprotein by advanced glycation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency
85. Advanced glycation end-products: A highly complex set of biologically relevant compounds detected by mass spectrometry